Back to search

Article

Expanding the options for therapeutic exon skipping as a future treatment for <i>USH2A</i> -associated disease by 3D structural modeling of newly formed hybrid domains

2026-04-28

Abstract excerpt

<h4>ABSTRACT</h4> Usher syndrome, the leading cause of hereditary deaf-blindness affecting approximately 1 in 15,000 individuals worldwide, is currently still untreatable. Antisense oligonucleotide-based exon skipping has shown significant therapeutic promise for USH2A -associated retinal dysfunction. Selection of (combinations of) exons suitable for therapeutic exon skipping within the fibronectin type 3 (FN3)...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
eb06d78d-7dc0-5038-99ab-6a657d19c3f7
DOI
10.64898/2026.04.24.720583
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Expanding the options for therapeutic exon skipping as a future treatment for <i>USH2A</i> -associated disease by 3D structural modeling of newly formed hybrid domainsDOI 10.64898/2026.04.24.720583
Select a neighboring publication to make it the new centre.